Pfizer

In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations. 

Though enrollment for the SAVOIR trial stopped early, results suggest that MET-driven advanced papillary renal cell carcinomas respond to savolitinib.

In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.

Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.

Encorafenib (Pfizer/Array BioPharma's Braftovi) is approved in combination with cetuximab (Eli Lilly's Erbitux) for previously treated patients.

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

In the upcoming clinical trial, the companies will evaluate the effects of IDEAYA's PKC inhibitor IDE196 and Pfizer's MEK inhibitor binimetinib.

In NSCLC driven by MET exon 14 alterations, research indicates Xalkori had some activity.